Serum BDNF levels before treatment predict SSRI response in depression
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVES The “neurotrophin hypothesis” of depression posits a role of brain-derived neurotrophic factor (BDNF) in depression, although it is unknown whether BDNF is more involved in the etiology of depression or in the mechanism of action of antidepressants. . It is also unknown whether pre-treatment serum BDNF levels predict antidepressant response. METHODS Thirty un-medicated depressed subjects were treated with escitalopram (N=16) or sertraline (N=14) for eight weeks. Twenty-five of the depressed subjects completed 8 weeks of antidepressant treatment and had analyzable data. Twenty-eight healthy controls were also studied. Serum for BDNF assay was obtained at baseline in all subjects and after 8 weeks of treatment in the depressed subjects. Depression ratings were obtained at baseline and after 8 weeks of treatment in the depressed subjects. RESULTS Pre-treatment BDNF levels were lower in the depressed subjects than the controls (p= 0.001) but were not significantly correlated with pre-treatment depression severity. Depression ratings improved with SSRI treatment (p< 0.001), and BDNF levels increased with treatment (p= 0.005). Changes in BDNF levels were not significantly correlated with changes in depression ratings. However, pre-treatment BDNF levels were directly correlated with antidepressant responses (p<0.01), and “Responders” to treatment (≥ 50% improvement in depression ratings) had higher pre-treatment BDNF levels than did “Non-responders” (p< 0.05). CONCLUSIONS These results confirm low serum BDNF levels in unmedicated depressed subjects and confirm antidepressant-induced increases in BDNF levels, but they suggest that antidepressants do not work simply by correcting BDNF insufficiency. Rather, these findings are consistent with a permissive or facilitatory role of BDNF in the mechanism of action of antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 3×
“…lowering brain BDNF (or lowering expression of its high affinity receptor, tyrosine kinase TrkB, in neural progenitor cells in the hippocampus) or inhibiting neurogenesis diminishes antidepressant efficacy inanimalmodels (Adachi et al., 2008; Li et al., 2008; Santarelli et al., 2003).”
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 2×
“However, this effect may be region-specific (hippocampal), since other pre-clinical animal studies suggest that BDNF knockout in the accumbens is anti-depressive (Berton et al., 2006; Govindarajan et al., 2006; Krishnan et al., 2007; Krishnan and Nestler, 2008).”
Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129
Decreased serum brain-derived neurotrophic factor levels in major depressed patients
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J.-M. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00005-7 · Cited by 1,232 · cited 2×
“…et al., 2007; Molendijk et al., 2010; Monteleone et al., 2008; Piccinni et al., 2009) but not with others (Gervasoni et al., 2005; Gonul et al., 2005; Huang et al., 2008; Karege et al., 2002; Lee andKim,2008; Lee andKim,2008;Matrisciano et al., 2009; Shimizu et al., 2003; Yoshimura et al., 2007).”
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
New insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 8×
“For example, there is little convincing evidence that inhibition of BDNF signaling leads to depression (Martinowich et al., 2007) (although see (Taliaz et al., 2010)).”
InfluentialAdult hippocampal neurogenesis in depression
Sahay, A., & Hen, R. (2007) · Nature Neuroscience · doi:10.1038/nn1969 · Cited by 1,206 · cited 2×
“, 2007), and evidence is more consistentwith BDNF involvement in certain antidepressant actions than in causing depression (Groves, 2007; Henn and Vollmayr, 2004a; Henn and Vollmayr, 2004b; Larsen et al., 2010; Li et al., 2008; Sahay and Hen, 2007).”
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151
Cited by
Molendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“As a potential biomarker, BDNF shows decreased levels in the blood of depressed patients and this can predict treatment response for escitalopram, paroxetine, and sertraline (Yoshimura et al., 2010; Wolkowitz et al., 2011; Yasui-Furukori et al., 2011).”
BackgroundBDNF in sleep, insomnia, and sleep deprivation
Schmitt, K., Holsboer-Trachsler, E., & Eckert, A. (2016) · Annals of Medicine · doi:10.3109/07853890.2015.1131327 · Cited by 273
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Zhou, C., Zhong, J., Zou, B., Fang, L., Chen, J., Deng, X., Zhang, L., Zhao, X., Qu, Z., Lei, Y., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172270 · Cited by 187
The role of exercise in the treatment of depression: biological underpinnings and clinical outcomes
Ross, R. E., VanDerwerker, C. J., Saladin, M. E., & Gregory, C. M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01819-w · Cited by 176
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis
Cattaneo, A., Macchi, F., Plazzotta, G., Veronica, B., Bocchio-Chiavetto, L., Riva, M. A., & Pariante, C. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00040 · Cited by 152
“A number of experimental studies have shown that defective BDNF expression or release may limit the antidepressant activity (Wolkowitz et al., 2011; Dreimüller et al., 2012), suggesting that neurotrophin modulation may represent an important mechanism of antidepressant drugs.”
BackgroundDuclot, F., & Kabbaj, M. (2015) · Journal of Experimental Biology · doi:10.1242/jeb.107086 · Cited by 103
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Gill, H., Gill, B., Rodrigues, N. B., Lipsitz, O., Rosenblat, J. D., El-Halabi, S., Nasri, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.020 · Cited by 93
Mosiołek, A., Mosiołek, J., Jakima, S., Pięta, A., & Szulc, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153377 · Cited by 87
Dionisie, V., Ciobanu, A. M., Toma, V. A., Manea, M. C., Baldea, I., Olteanu, D., Sevastre-Berghian, A., Clichici, S., Manea, M., Riga, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147483 · Cited by 78
Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhan, Y., Li, H., Chen, L., Li, M., & Ning, Y. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798614 · Cited by 73
Longitudinal multi-level biomarker analysis of BDNF in major depression and bipolar disorder
Schröter, K., Brum, M., Brunkhorst-Kanaan, N., Tole, F., Ziegler, C., Domschke, K., Reif, A., & Kittel-Schneider, S. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01007-y · Cited by 68
Haghighi, M., Khodakarami, S., Jahangard, L., Ahmadpanah, M., Bajoghli, H., Holsboer-Trachsler, E., & Brand, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.018 · Cited by 65
Monteiro, B. C., Monteiro, S., Candida, M., Adler, N., Paes, F., Rocha, N., Nardi, A. E., Murillo-Rodriguez, E., & Machado, S. (2017) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901713010213 · Cited by 63
Gupta, R., Gupta, K., Tripathi, A. K., Bhatia, M. S., & Gupta, L. K. (2016) · Pharmacology · doi:10.1159/000444220 · Cited by 61
Brunoni, A. R., Machado-Vieira, R., Zarate, C. A., Vieira, E. L. M., Vanderhasselt, M.-A., Nitsche, M. A., Valiengo, L., Benseñor, I. M., Lotufo, P. A., Gattaz, W. F., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.006 · Cited by 60
Zelada, M. I., Garrido, V., Liberona, A., Jones, N., Zúñiga, K., Silva, H., & Nieto, R. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914810 · Cited by 60
Husain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1076459 · Cited by 50
High-Intensity Aerobic Exercise Acutely Increases Brain-derived Neurotrophic Factor
ROSS, R. E., SALADIN, M. E., GEORGE, M. S., & GREGORY, C. M. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001969 · Cited by 50
Hing, B., Gardner, C., & Potash, J. B. (2014) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32265 · Cited by 47
Liu, W., Zhou, Y., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Li, H., Chen, L., & Ning, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.012 · Cited by 45
Francazio (2015) · doi:10.1016/j.psychres.2015.04.009 · Cited by 35
Smit, A. J. T., Wu, G. W. Y., Rampersaud, R., Reus, V. I., Wolkowitz, O. M., & Mellon, S. H. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107045 · Cited by 9
“Furthermore, high BDNF pre-treatment levels predicted better response to treatment with SSRIs in several studies (Mikoteit et al., 2014; Ramesh et al., 2021), including an earlier study of ours (Wolkowitz et al., 2011).”
Self-citation
Metadata
- Authors
- Wolkowitz, O. M., Wolf, J., Shelly, W., Rosser, R., Burke, H. M., Lerner, G. K., Reus, V. I., Nelson, J. C., Epel, E. S., & Mellon, S. H.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 35
- Issue
- 7
- Pages
- 1623-1630
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2083451860
- Cited by
- 174
- References
- 26
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.